Cargando…

Representativeness of the GALACTIC‐HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction

BACKGROUND: Randomized clinical trials in populations with heart failure with reduced ejection fraction may not be reflective of the general population with heart failure with reduced ejection fraction. Our study assessed the representativeness of the GALACTIC‐HF (Global Approach to Lowering Adverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mefford, Matthew T., Koyama, Sandra Y., De Jesus, Justine, Wei, Rong, Fischer, Heidi, Harrison, Teresa N., Woo, Pauline, Reynolds, Kristi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075481/ https://www.ncbi.nlm.nih.gov/pubmed/35322672 http://dx.doi.org/10.1161/JAHA.121.023766

Ejemplares similares

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
por: Teerlink, John R., et al.
Publicado: (2020)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Workshop on Mass Ejection from Active Galactic Nuclei
por: Arav, N, et al.
Publicado: (1997)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Comment on "The neutrino fraction in our galactic halo"
por: Ellis, Jonathan Richard, et al.
Publicado: (1994)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
por: Camps-Vilaró, Anna, et al.
Publicado: (2020)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF
por: Fudim, Marat, et al.
Publicado: (2020)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Impact of adherence to guideline‐directed therapy on risk of death in HF patients across an ejection fraction spectrum
por: Chen, Xiaojing, et al.
Publicado: (2023)

Extraction of Ejection Fraction from Echocardiography Notes for Constructing a Cohort of Patients having Heart Failure with reduced Ejection Fraction (HFrEF)
por: Wagholikar, Kavishwar B., et al.
Publicado: (2018)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Galactic and extra-galactic radio astronomy
por: Verschuur, Gerrit, et al.
Publicado: (1974)

Phenotyping of Sleep‐Disordered Breathing in Patients With Chronic Heart Failure With Reduced Ejection Fraction—the SchlaHF Registry
por: Arzt, Michael, et al.
Publicado: (2017)

Prognostic value of heart failure echocardiography index in HF patients with preserved, mid-ranged and reduced ejection fraction
por: Chen, Jian-Shu, et al.
Publicado: (2020)

Endovascular renal sympathetic denervation to improve heart failure with reduced ejection fraction: the IMPROVE-HF-I study
por: Feyz, L., et al.
Publicado: (2021)

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022)

Galactics
Publicado: (1861)

Outcomes of patients with anemia and renal dysfunction in hospitalized heart failure with preserved ejection fraction (from the CN-HF registry)
por: Jin, Xuejuan, et al.
Publicado: (2019)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry
Publicado: (2020)

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2020)

Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study
por: van Veldhuisen, Dirk J., et al.
Publicado: (2020)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry
por: MacDonald, Michael R., et al.
Publicado: (2019)

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
por: Mooney, Leanne, et al.
Publicado: (2021)

Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry
por: Uijl, A., et al.
Publicado: (2021)

Polypill Eligibility for Patients with Heart Failure with Reduced Ejection Fraction in the ASIAN-HF Registry: A Cross-Sectional Analysis
por: Vijay, Aishwarya, et al.
Publicado: (2023)

Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
por: Yeoh, Su Ern, et al.
Publicado: (2023)

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
por: Nassif, Michael E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8533s4cp0q24f39sjr17a0pf0